Welcome to Peptide Card of AntiTbPdb
| This page displays user query in tabular form. |
(METH-Ala)-(D-Pip)-L-(D-VAL)-Pip-(D-Pip) details |
| Primary information | |
|---|---|
| ID | antitb_1832, |
| Name | 24224794 |
| N-Terminal modification | Hytramycin V |
| C-Terminal Modification | (METH-Ala)-(D-Pip)-L-(D-VAL)-Pip-(D-Pip) |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | METH-ALA= Methylated alanine, D-Pip = piperazic acid moieties |
| Chirality | Cyclic (Intrachain bond between 1-6) |
| Nature | 6 |
| Source | Mix |
| Species | Natural |
| Strain | From Streptomyces hygroscopicus strain ECUM 14046 |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv |
| Cell Line | MIC = 11.3 μg/mL |
| Inhibition Concentration | In vitro |
| Sequence | 2013 |
| Cytotoxicity | None |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Antibacterial (Escherichia coli (ATCC 25922), Staphylococcus aureus (ATCC 29213), Acinetobacter baumannii (ATCC BAA-747), Enterococcus faecalis (ATCC 29212), and Pseudomonas aeruginosa (ATCC 27853) |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1833, |
| Name | 24224794 |
| N-Terminal modification | Hytramycin V |
| C-Terminal Modification | (METH-Ala)-(D-Pip)-L-(D-VAL)-Pip-(D-Pip) |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | METH-ALA= Methylated alanine, D-Pip = piperazic acid moieties |
| Chirality | Cyclic (Intrachain bond between 1-6) |
| Nature | 6 |
| Source | Mix |
| Species | Natural |
| Strain | From Streptomyces hygroscopicus strain ECUM 14046 |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Clinical isolate, X004439 |
| Cell Line | MIC = 9.3 μg/mL |
| Inhibition Concentration | In vitro |
| Sequence | 2013 |
| Cytotoxicity | None |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Antibacterial (Escherichia coli (ATCC 25922), Staphylococcus aureus (ATCC 29213), Acinetobacter baumannii (ATCC BAA-747), Enterococcus faecalis (ATCC 29212), and Pseudomonas aeruginosa (ATCC 27853) |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1834, |
| Name | 24224794 |
| N-Terminal modification | Hytramycin V |
| C-Terminal Modification | (METH-Ala)-(D-Pip)-L-(D-VAL)-Pip-(D-Pip) |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | METH-ALA= Methylated alanine, D-Pip = piperazic acid moieties |
| Chirality | Cyclic (Intrachain bond between 1-6) |
| Nature | 6 |
| Source | Mix |
| Species | Natural |
| Strain | From Streptomyces hygroscopicus strain ECUM 14046 |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Clinical isolate, X004244 |
| Cell Line | MIC = 16.9 μg/mL |
| Inhibition Concentration | In vitro |
| Sequence | 2013 |
| Cytotoxicity | None |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Antibacterial (Escherichia coli (ATCC 25922), Staphylococcus aureus (ATCC 29213), Acinetobacter baumannii (ATCC BAA-747), Enterococcus faecalis (ATCC 29212), and Pseudomonas aeruginosa (ATCC 27853) |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1835, |
| Name | 24224794 |
| N-Terminal modification | Hytramycin V |
| C-Terminal Modification | (METH-Ala)-(D-Pip)-L-(D-VAL)-Pip-(D-Pip) |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | METH-ALA= Methylated alanine, D-Pip = piperazic acid moieties |
| Chirality | Cyclic (Intrachain bond between 1-6) |
| Nature | 6 |
| Source | Mix |
| Species | Natural |
| Strain | From Streptomyces hygroscopicus strain ECUM 14046 |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Clinical isolate, X005282 |
| Cell Line | MIC = 9.6 μg/mL |
| Inhibition Concentration | In vitro |
| Sequence | 2013 |
| Cytotoxicity | None |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Antibacterial (Escherichia coli (ATCC 25922), Staphylococcus aureus (ATCC 29213), Acinetobacter baumannii (ATCC BAA-747), Enterococcus faecalis (ATCC 29212), and Pseudomonas aeruginosa (ATCC 27853) |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1836, |
| Name | 24224794 |
| N-Terminal modification | Hytramycin V |
| C-Terminal Modification | (METH-Ala)-(D-Pip)-L-(D-VAL)-Pip-(D-Pip) |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | METH-ALA= Methylated alanine, D-Pip = piperazic acid moieties |
| Chirality | Cyclic (Intrachain bond between 1-6) |
| Nature | 6 |
| Source | Mix |
| Species | Natural |
| Strain | From Streptomyces hygroscopicus strain ECUM 14046 |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Clinical isolate, X005319 |
| Cell Line | MIC = 19.2 μg/mL |
| Inhibition Concentration | In vitro |
| Sequence | 2013 |
| Cytotoxicity | None |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Antibacterial (Escherichia coli (ATCC 25922), Staphylococcus aureus (ATCC 29213), Acinetobacter baumannii (ATCC BAA-747), Enterococcus faecalis (ATCC 29212), and Pseudomonas aeruginosa (ATCC 27853) |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1837, |
| Name | 24224794 |
| N-Terminal modification | Hytramycin V |
| C-Terminal Modification | (METH-Ala)-(D-Pip)-L-(D-VAL)-Pip-(D-Pip) |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | METH-ALA= Methylated alanine, D-Pip = piperazic acid moieties |
| Chirality | Cyclic (Intrachain bond between 1-6) |
| Nature | 6 |
| Source | Mix |
| Species | Natural |
| Strain | From Streptomyces hygroscopicus strain ECUM 14046 |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Clinical isolate, X001354 |
| Cell Line | MIC = 9.7 μg/mL |
| Inhibition Concentration | In vitro |
| Sequence | 2013 |
| Cytotoxicity | None |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Antibacterial (Escherichia coli (ATCC 25922), Staphylococcus aureus (ATCC 29213), Acinetobacter baumannii (ATCC BAA-747), Enterococcus faecalis (ATCC 29212), and Pseudomonas aeruginosa (ATCC 27853) |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1838, |
| Name | 24224794 |
| N-Terminal modification | Hytramycin V |
| C-Terminal Modification | (METH-Ala)-(D-Pip)-L-(D-VAL)-Pip-(D-Pip) |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | METH-ALA= Methylated alanine, D-Pip = piperazic acid moieties |
| Chirality | Cyclic (Intrachain bond between 1-6) |
| Nature | 6 |
| Source | Mix |
| Species | Natural |
| Strain | From Streptomyces hygroscopicus strain ECUM 14046 |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Clinical isolate, X003899 |
| Cell Line | MIC = 22.9 μg/mL |
| Inhibition Concentration | In vitro |
| Sequence | 2013 |
| Cytotoxicity | None |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Antibacterial (Escherichia coli (ATCC 25922), Staphylococcus aureus (ATCC 29213), Acinetobacter baumannii (ATCC BAA-747), Enterococcus faecalis (ATCC 29212), and Pseudomonas aeruginosa (ATCC 27853) |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1839, |
| Name | 24224794 |
| N-Terminal modification | Hytramycin V |
| C-Terminal Modification | (METH-Ala)-(D-Pip)-L-(D-VAL)-Pip-(D-Pip) |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | METH-ALA= Methylated alanine, D-Pip = piperazic acid moieties |
| Chirality | Cyclic (Intrachain bond between 1-6) |
| Nature | 6 |
| Source | Mix |
| Species | Natural |
| Strain | From Streptomyces hygroscopicus strain ECUM 14046 |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis resistant to streptomycin (rSM, ATCC 35820) |
| Cell Line | MIC = 11.6 μg/mL |
| Inhibition Concentration | In vitro |
| Sequence | 2013 |
| Cytotoxicity | None |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Antibacterial (Escherichia coli (ATCC 25922), Staphylococcus aureus (ATCC 29213), Acinetobacter baumannii (ATCC BAA-747), Enterococcus faecalis (ATCC 29212), and Pseudomonas aeruginosa (ATCC 27853) |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1840, |
| Name | 24224794 |
| N-Terminal modification | Hytramycin V |
| C-Terminal Modification | (METH-Ala)-(D-Pip)-L-(D-VAL)-Pip-(D-Pip) |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | METH-ALA= Methylated alanine, D-Pip = piperazic acid moieties |
| Chirality | Cyclic (Intrachain bond between 1-6) |
| Nature | 6 |
| Source | Mix |
| Species | Natural |
| Strain | From Streptomyces hygroscopicus strain ECUM 14046 |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis resistant to rifampin (rRMP, ATCC 35838) |
| Cell Line | MIC = 9.6 μg/mL |
| Inhibition Concentration | In vitro |
| Sequence | 2013 |
| Cytotoxicity | None |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Antibacterial (Escherichia coli (ATCC 25922), Staphylococcus aureus (ATCC 29213), Acinetobacter baumannii (ATCC BAA-747), Enterococcus faecalis (ATCC 29212), and Pseudomonas aeruginosa (ATCC 27853) |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1841, |
| Name | 24224794 |
| N-Terminal modification | Hytramycin V |
| C-Terminal Modification | (METH-Ala)-(D-Pip)-L-(D-VAL)-Pip-(D-Pip) |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | METH-ALA= Methylated alanine, D-Pip = piperazic acid moieties |
| Chirality | Cyclic (Intrachain bond between 1-6) |
| Nature | 6 |
| Source | Mix |
| Species | Natural |
| Strain | From Streptomyces hygroscopicus strain ECUM 14046 |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis resistant to kanamycin (rKM, ATCC 35827) |
| Cell Line | MIC = 12.4 μg/mL |
| Inhibition Concentration | In vitro |
| Sequence | 2013 |
| Cytotoxicity | None |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Antibacterial (Escherichia coli (ATCC 25922), Staphylococcus aureus (ATCC 29213), Acinetobacter baumannii (ATCC BAA-747), Enterococcus faecalis (ATCC 29212), and Pseudomonas aeruginosa (ATCC 27853) |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1842, |
| Name | 24224794 |
| N-Terminal modification | Hytramycin V |
| C-Terminal Modification | (METH-Ala)-(D-Pip)-L-(D-VAL)-Pip-(D-Pip) |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | METH-ALA= Methylated alanine, D-Pip = piperazic acid moieties |
| Chirality | Cyclic (Intrachain bond between 1-6) |
| Nature | 6 |
| Source | Mix |
| Species | Natural |
| Strain | From Streptomyces hygroscopicus strain ECUM 14046 |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis resistant to isoniazid (rINH, ATCC 35822) |
| Cell Line | MIC = 12.1 μg/mL |
| Inhibition Concentration | In vitro |
| Sequence | 2013 |
| Cytotoxicity | None |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Antibacterial (Escherichia coli (ATCC 25922), Staphylococcus aureus (ATCC 29213), Acinetobacter baumannii (ATCC BAA-747), Enterococcus faecalis (ATCC 29212), and Pseudomonas aeruginosa (ATCC 27853) |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1843, |
| Name | 24224794 |
| N-Terminal modification | Hytramycin V |
| C-Terminal Modification | (METH-Ala)-(D-Pip)-L-(D-VAL)-Pip-(D-Pip) |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | METH-ALA= Methylated alanine, D-Pip = piperazic acid moieties |
| Chirality | Cyclic (Intrachain bond between 1-6) |
| Nature | 6 |
| Source | Mix |
| Species | Natural |
| Strain | From Streptomyces hygroscopicus strain ECUM 14046 |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis resistant to cycloserine (rCS, ATCC 35826) |
| Cell Line | MIC = 20.6 μg/mL |
| Inhibition Concentration | In vitro |
| Sequence | 2013 |
| Cytotoxicity | None |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Antibacterial (Escherichia coli (ATCC 25922), Staphylococcus aureus (ATCC 29213), Acinetobacter baumannii (ATCC BAA-747), Enterococcus faecalis (ATCC 29212), and Pseudomonas aeruginosa (ATCC 27853) |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1844, |
| Name | 24224794 |
| N-Terminal modification | Hytramycin V |
| C-Terminal Modification | (METH-Ala)-(D-Pip)-L-(D-VAL)-Pip-(D-Pip) |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | METH-ALA= Methylated alanine, D-Pip = piperazic acid moieties |
| Chirality | Cyclic (Intrachain bond between 1-6) |
| Nature | 6 |
| Source | Mix |
| Species | Natural |
| Strain | From Streptomyces hygroscopicus strain ECUM 14046 |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis resistant to moxifloxacin (rMOX) |
| Cell Line | MIC = 9.0 μg/mL |
| Inhibition Concentration | In vitro |
| Sequence | 2013 |
| Cytotoxicity | None |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Antibacterial (Escherichia coli (ATCC 25922), Staphylococcus aureus (ATCC 29213), Acinetobacter baumannii (ATCC BAA-747), Enterococcus faecalis (ATCC 29212), and Pseudomonas aeruginosa (ATCC 27853) |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1845, |
| Name | 24224794 |
| N-Terminal modification | Hytramycin V |
| C-Terminal Modification | (METH-Ala)-(D-Pip)-L-(D-VAL)-Pip-(D-Pip) |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | METH-ALA= Methylated alanine, D-Pip = piperazic acid moieties |
| Chirality | Cyclic (Intrachain bond between 1-6) |
| Nature | 6 |
| Source | Mix |
| Species | Natural |
| Strain | From Streptomyces hygroscopicus strain ECUM 14046 |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis resistant to capreomycin (rCAP) |
| Cell Line | MIC = 12.1 μg/mL |
| Inhibition Concentration | In vitro |
| Sequence | 2013 |
| Cytotoxicity | None |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Antibacterial (Escherichia coli (ATCC 25922), Staphylococcus aureus (ATCC 29213), Acinetobacter baumannii (ATCC BAA-747), Enterococcus faecalis (ATCC 29212), and Pseudomonas aeruginosa (ATCC 27853) |
| Tertiary Structure (Technique) | Not Predicted), |